SanBio Company Limited

Equities

4592

JP3336750009

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-02 am EDT			5-day change	1st Jan Change
430 ^JPY	+2.38%		+2.63%	-38.75%

Mar. 19	SanBio Eyes Approval for Brain Injury Treatment Drug SB623 By March	MT
Mar. 19	Jefferies Adjusts SanBio’s Price Target to 270 Yen From 310 Yen, Keeps at Underperform	MT

SanBio Company Limited Announces Consolidated Earnings Results for the Fiscal Year Ended January 31, 2021

March 17, 2021 at 02:00 am EDT

SanBio Company Limited announced consolidated earnings results for the fiscal year ended January 31, 2021. For the period, the company reported operating loss was JPY 5,801,740,000 against JPY 5,486,070,000 a year ago. Net loss was JPY 3,385,875,000 compared to JPY 5,157,716,000 a year ago. Net loss per share was JPY 65.38 compared to JPY 100.91 per share a year ago.

Latest news about SanBio Company Limited

SanBio Eyes Approval for Brain Injury Treatment Drug SB623 By March	Mar. 19	MT
Jefferies Adjusts SanBio’s Price Target to 270 Yen From 310 Yen, Keeps at Underperform	Mar. 19	MT
Transcript : SanBio Company Limited, 2024 Earnings Call, Mar 19, 2024	Mar. 19
SanBio Books Non-operating Income, Extraordinary Gains, Deferred Income Taxes in Fiscal 2024	Mar. 18	MT
SanBio's FY2024 Attributable Net Loss Narrows on Lower Costs, Forex Gains	Mar. 18	MT
Sanbio Company Limited Provides Consolidated Earnings Guidance for the First Half of Fiscal Year Ending January 31, 2025, and Full Fiscal Year Ending January 31, 2025	Mar. 18	CI
SanBio Liquidates Singapore Unit	Feb. 14	MT
Sanbio Co., Ltd. Provides Update on Status of Manufacturing and Marketing Approval for Sb623 Chronic Traumatic Brain Injury Program in Japan	Jan. 25	CI
SanBio to Cancel Certain Stock Options	Jan. 10	MT
SanBio Logs Extraordinary Gain from Asset Sale of US Unit	Dec. 21	MT
Sanbio Widens Nine-Month Attributable Net Loss	Dec. 15	MT
Sanbio Cuts Staff Amid Restructuring of Overseas Subsidiary	Dec. 14	MT
Sanbio Expects to Receive Regulatory Nod for Stem Cell Therapy Candidate in March 2024	Dec. 14	MT
SanBio Company Limited Provides Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury Program in Japan	Dec. 14	CI
Jefferies Adjusts Sanbio’ Price Target to 310 Yen From 420 Yen, Keeps at Underperform	23-10-25	MT
Transcript : SanBio Company Limited, Q2 2024 Earnings Call, Sep 15, 2023	23-09-15
Jefferies Adjusts SanBio's Price Target to 420 Yen From 550 Yen, Keeps at Underperform	23-07-28	MT
SanBio's Overseas Subsidiary to Carry Out Personnel Reduction by November	23-07-12	MT
SanBio Co., Ltd. Updates on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic Brain Injury Program in Japan	23-06-14	CI
SanBio Company Limited Provides Consolidated Earnings Guidance for the First Half and Full Year Ending January 31, 2024	23-06-14	CI
Japan Stock Market Remains Jittery Despite Damage Control; Toyota Industries Plummets 11% Over Fresh Data Scandal	23-03-20	MT
SanBio to Wind Up Singapore Unit	23-03-20	MT
SanBio's FY23 Loss Widens	23-03-20	MT
Transcript : SanBio Company Limited, 2023 Earnings Call, Mar 17, 2023	23-03-17
Sanbio Company Limited Provides Consolidated Earnings Guidance for the First Half of Fiscal Year Ending January 31, 2024, and Full Fiscal Year Ending January 31, 2024	23-03-17	CI

Chart SanBio Company Limited

Duration

Period

More charts

Company Profile

SanBio Co Ltd is engaged in the regenerative cell business using allogeneic stem cells. The Company has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The Company aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. It is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The Company has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).

Sector

Biotechnology & Medical Research

Calendar

2024-06-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

430 JPY

Average target price

800 JPY

Spread / Average Target

+86.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SANBIO COMPANY LIMITED	-38.75%	193M
REGENERON PHARMACEUTICALS, INC.	+8.90%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.13%	104B
ARGENX SE	+5.79%	22.94B
BIONTECH SE	-12.36%	22.34B
GENMAB A/S	-7.01%	19.25B
WUXI APPTEC CO., LTD.	-37.08%	17.08B
BEIGENE, LTD.	-9.04%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+7.83%	14.16B
SAREPTA THERAPEUTICS, INC.	+38.71%	12.63B

Bio Therapeutic Drugs